SBIR Phase I: Prostate cancer diagnosis with an integrated endorectal MRI and targeted transrectal biopsy

这个小型企业创新研究（SBIR）第一阶段项目的更广泛的影响/商业潜力是改善前列腺癌的检测，前列腺癌是男性中一种高度流行的致命癌症。在美国，每年进行大约一百万次前列腺活检。不幸的是，标准诊断方法不精确且效率低下。拟议的项目将推进一种新的方法，使用磁共振成像（MRI）靶向活检，以提高检测。 该小型企业创新研究（SBIR）I期项目将通过开发一种系统来推进前列腺癌的诊断，该系统将直肠内MRI线圈和经直肠活检针导的多通道阵列相结合，并允许将直肠内MRI与孔内活检作为一个单一的快速集成程序。该项目将推进一种最佳结合直肠内MRI和MRI靶向活检的程序。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to improve detection of prostate cancer, a highly prevalent fatal cancer in men. Approximately one million prostate biopsies are performed annually in the U.S. Unfortunately the standard diagnostic method is imprecise and inefficient. The proposed project will advance a new method that uses Magnetic Resonance Imaging (MRI) to target biopsies for improved detection. This Small Business Innovation Research (SBIR) Phase I project will advance diagnosis of prostate cancer by developing a system that combines an endorectal MRI coil and a multichannel array of transrectal biopsy needle guides and allows for endorectal MRI with in-bore biopsy as a single rapid integrated procedure. The project will advance a procedure that optimally combines endorectal MRI and MRI-targeted biopsy.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.